Group A streptococcal vaccines: facts versus fantasy

Steer, Andrew C., Batzloff, Michael R., Mulholland, Kim and Carapetis, Jonathan R. (2009) Group A streptococcal vaccines: facts versus fantasy. Current Opinion in Infectious Diseases, 22 6: 544-552. doi:10.1097/QCO.0b013e328332bbfe

Author Steer, Andrew C.
Batzloff, Michael R.
Mulholland, Kim
Carapetis, Jonathan R.
Title Group A streptococcal vaccines: facts versus fantasy
Journal name Current Opinion in Infectious Diseases   Check publisher's open access policy
ISSN 0951-7375
Publication date 2009-12
Sub-type Critical review of research, literature review, critical commentary
DOI 10.1097/QCO.0b013e328332bbfe
Volume 22
Issue 6
Start page 544
End page 552
Total pages 9
Place of publication Philadelphia, PA, United States
Publisher Lippincott Williams & Wilkins
Language eng
Formatted abstract
Purpose of review: This review provides an overview of progress of the development of group A streptococcal (GAS) vaccines with a focus on recent advances.

Recent findings: Historically, GAS vaccine development has focused on the N-terminus of the M protein, which ultimately led to successful phase I/II clinical trials of a 26-valent recombinant M protein vaccine in 2004–2005. More recently, interest in antigens conserved among most, if not all, group A streptococci has increased. However, no vaccines containing these antigens have reached clinical trials. Three strategies have been used to develop conserved antigen vaccine candidates: use of the conserved region of the M protein; use of well described virulence factors as antigens, including streptococcal C5a peptidase, streptococcal carbohydrate, fibronectin-binding proteins, cysteine protease and streptococcal pili; and use of reverse vaccinology to identify novel antigens.

Summary: Several vaccine candidates against GAS infection are in varying stages of preclinical and clinical development. Although there is great hope that one of these vaccine candidates will reach licensure in the next decade, only one, the multivalent N-terminal vaccine, has entered clinical trials in the last 30 years. Although strong advocacy for GAS vaccine development is important, there remains an urgent need to institute available public health control measures against GAS diseases globally, particularly in developing countries.
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collections: ERA 2012 Admin Only
School of Public Health Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 56 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 59 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 25 Oct 2011, 09:43:35 EST by Geraldine Fitzgerald on behalf of School of Public Health